Glaukos (GKOS)
(Delayed Data from NYSE)
$130.98 USD
+4.18 (3.30%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $130.94 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$130.98 USD
+4.18 (3.30%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $130.94 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -20.69% and 8.83%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 4 Medical Device Stocks in Q1 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how the four medical device stocks, COR, GKOS, ARAY and SRDX, might fare in their quarterly results slated to be release tomorrow.
Can the 4 Medical Device Stocks Hit Targets This Earnings Season?
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, GKOS, SRDX and ARAY are placed ahead of their earnings releases.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?
by Zacks Equity Research
Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS
by Zacks Equity Research
Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.
Glaukos (GKOS) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) fourth-quarter revenues beat estimates as well as gained year over year. Gross margin improve, while higher operating expenses lead to a wider operating loss.
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -12.50% and 1.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology (TCMD) Beats Q4 Earnings Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 192.31% and 1.51%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
The Zacks Analyst Blog Highlights Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics
by Zacks Equity Research
Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics are included in this Analyst Blog.
What's in Store for West Pharmaceutical (WST) in Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
3 Medtech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand
by Zacks Equity Research
Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
by Zacks Equity Research
The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.
Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Why Is Glaukos (GKOS) Down 0.4% Since Last Earnings Report?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.